These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 32241247

  • 1. Exploring the interaction of Peloruside-A with drug resistant αβII and αβIII tubulin isotypes in human ovarian carcinoma using a molecular modeling approach.
    Kumbhar BV, Bhandare VV.
    J Biomol Struct Dyn; 2021 Apr; 39(6):1990-2002. PubMed ID: 32241247
    [Abstract] [Full Text] [Related]

  • 2. βII-tubulin and βIII-tubulin mediate sensitivity to peloruside A and laulimalide, but not paclitaxel or vinblastine, in human ovarian carcinoma cells.
    Kanakkanthara A, Northcote PT, Miller JH.
    Mol Cancer Ther; 2012 Feb; 11(2):393-404. PubMed ID: 22180309
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Interaction of microtubule depolymerizing agent indanocine with different human αβ tubulin isotypes.
    Kumbhar BV, Panda D, Kunwar A.
    PLoS One; 2018 Feb; 13(3):e0194934. PubMed ID: 29584771
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Novel mutations involving βI-, βIIA-, or βIVB-tubulin isotypes with functional resemblance to βIII-tubulin in breast cancer.
    Wang W, Zhang H, Wang X, Patterson J, Winter P, Graham K, Ghosh S, Lee JC, Katsetos CD, Mackey JR, Tuszynski JA, Wong GK, Ludueña RF.
    Protoplasma; 2017 May; 254(3):1163-1173. PubMed ID: 27943021
    [Abstract] [Full Text] [Related]

  • 9. Computational study of interactions of anti-cancer drug eribulin with human tubulin isotypes.
    Rai K, Kumbhar BV, Panda D, Kunwar A.
    Phys Chem Chem Phys; 2022 Jul 13; 24(27):16694-16700. PubMed ID: 35766982
    [Abstract] [Full Text] [Related]

  • 10. Structural insight into the role of Gln293Met mutation on the Peloruside A/Laulimalide association with αβ-tubulin from molecular dynamics simulations, binding free energy calculations and weak interactions analysis.
    Zúñiga MA, Alderete JB, Jaña GA, Jiménez VA.
    J Comput Aided Mol Des; 2017 Jul 13; 31(7):643-652. PubMed ID: 28597356
    [Abstract] [Full Text] [Related]

  • 11. Molecular modeling study on the differential microtubule-stabilizing effect in singly- and doubly-bonded complexes with peloruside A and paclitaxel.
    Zúñiga MA, Alderete JB, Jaña GA, Navarrete KR, Jiménez VA.
    Proteins; 2019 Aug 13; 87(8):668-678. PubMed ID: 30958582
    [Abstract] [Full Text] [Related]

  • 12. Peloruside A does not bind to the taxoid site on beta-tubulin and retains its activity in multidrug-resistant cell lines.
    Gaitanos TN, Buey RM, Díaz JF, Northcote PT, Teesdale-Spittle P, Andreu JM, Miller JH.
    Cancer Res; 2004 Aug 01; 64(15):5063-7. PubMed ID: 15289305
    [Abstract] [Full Text] [Related]

  • 13. Acquired resistance to peloruside A and laulimalide is associated with downregulation of vimentin in human ovarian carcinoma cells.
    Kanakkanthara A, Rawson P, Northcote PT, Miller JH.
    Pharm Res; 2012 Nov 01; 29(11):3022-32. PubMed ID: 22584948
    [Abstract] [Full Text] [Related]

  • 14. Docking and molecular dynamics studies of the binding between Peloruside A and tubulin.
    Liao SY, Mo GQ, Chen JC, Zheng KC.
    J Enzyme Inhib Med Chem; 2014 Oct 01; 29(5):702-9. PubMed ID: 24156744
    [Abstract] [Full Text] [Related]

  • 15. Resistance to peloruside A and laulimalide: functional significance of acquired βI-tubulin mutations at sites important for drug-tubulin binding.
    Kanakkanthara A, Eras J, Northcote PT, Cabral F, Miller JH.
    Curr Cancer Drug Targets; 2014 Oct 01; 14(1):79-90. PubMed ID: 24245693
    [Abstract] [Full Text] [Related]

  • 16. Peloruside A synergizes with other microtubule stabilizing agents in cultured cancer cell lines.
    Wilmes A, Bargh K, Kelly C, Northcote PT, Miller JH.
    Mol Pharm; 2007 Oct 01; 4(2):269-80. PubMed ID: 17397239
    [Abstract] [Full Text] [Related]

  • 17. Peloruside, laulimalide, and noscapine interactions with beta-tubulin.
    Gajewski MM, Alisaraie L, Tuszynski JA.
    Pharm Res; 2012 Nov 01; 29(11):2985-93. PubMed ID: 22733149
    [Abstract] [Full Text] [Related]

  • 18. Modulation of lateral and longitudinal interdimeric interactions in microtubule models by Laulimalide and Peloruside A association: A molecular modeling approach on the mechanism of microtubule stabilizing agents.
    Zúñiga MA, Alderete JB, Jaña GA, Fernandez PA, Ramos MJ, Jiménez VA.
    Chem Biol Drug Des; 2018 May 01; 91(5):1042-1055. PubMed ID: 29316292
    [Abstract] [Full Text] [Related]

  • 19. Elucidation of the anticancer potential and tubulin isotype-specific interactions of β-sitosterol.
    Pradhan M, Suri C, Choudhary S, Naik PK, Lopus M.
    J Biomol Struct Dyn; 2018 Jan 01; 36(1):195-208. PubMed ID: 27960611
    [Abstract] [Full Text] [Related]

  • 20. Mutations in the β-tubulin binding site for peloruside A confer resistance by targeting a cleft significant in side chain binding.
    Begaye A, Trostel S, Zhao Z, Taylor RE, Schriemer DC, Sackett DL.
    Cell Cycle; 2011 Oct 01; 10(19):3387-96. PubMed ID: 21926482
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.